Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(11):766-767; doi:10.1093/jnci/95.11.766
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wu, K.
Right arrow Articles by Brown, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, K.
Right arrow Articles by Brown, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 11, 766-767, June 4, 2003
© 2003 Oxford University Press

EDITORIAL

Is Low-Dose Tamoxifen Useful for the Treatment and Prevention of Breast Cancer?

Kendall Wu, Powel Brown

Affiliation of authors: K. Wu, P. Brown, Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.

Correspondence to: Powel Brown, M.D., Ph.D., Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, MS 600, Houston, TX 77030 (e-mail: pbrown@breastcenter.tmc.edu).

The first 10% of the full text of this article appears below.

Many studies have demonstrated the utility of tamoxifen for the treatment of estrogen receptor (ER)-positive breast cancer (1) and more recently for the prevention of breast cancer in women at increased risk (2–4). However, the toxicities of tamoxifen such as thromboembolic events and endometrial cancers still pose a clinically significant problem. To reduce the risk of these adverse events, effective, yet safe drugs are being sought that could replace tamoxifen. Indeed, new endocrine agents such as selective ER modulators (SERMs) and aromatase inhibitors are being evaluated as alternatives to tamoxifen for the treatment (5–9) and prevention (10) of breast cancer. In this issue of the Journal, Decensi et al. (11) propose a different strategy to reduce the side effects of tamoxifen. They suggest that, by using a lower dose . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?